Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
Division of Trauma, Emergency Surgery and Surgical Critical Care, Massachusetts General Hospital, Boston, MA, USA.
J Antimicrob Chemother. 2018 Jan 1;73(1):199-203. doi: 10.1093/jac/dkx356.
The most optimal method of attaining therapeutic vancomycin concentrations during continuous venovenous haemofiltration (CVVH) remains unclear. Studies have shown continuous infusion vancomycin (CIV) achieves target concentrations more rapidly and consistently when compared with intermittent infusion. Positive correlations between CVVH intensity and vancomycin clearance (CLvanc) have been noted. This study is the first to evaluate a CIV regimen in patients undergoing CVVH that incorporates weight-based CVVH intensity (mL/kg/h) into the dosing nomogram.
This was a prospective, observational study of patients undergoing CVVH and receiving CIV based on the nomogram. The primary outcome was achievement of a therapeutic vancomycin concentration (15-25 mg/L) at 24 h. Secondary outcomes included the achievement of therapeutic concentrations at 48 and 72 h.
The nomogram was analysed in 52 critically ill adults. Vancomycin concentrations were therapeutic in 43/52 patients (82.7%) at 24 h. Of the nine patients who were not therapeutic at 24 h, seven were supratherapeutic and two were subtherapeutic. The mean (SD) concentration was 20.1 (4.2) mg/L at 24 h, 20.7 (3.7) mg/L at 48 h and 21.9 (3.5) mg/L at 72 h. Patients with CVVH intensity >20 mL/kg/h experienced higher CLvanc at 24 h compared with patients with CVVH intensity <20 mL/kg/h (3.1 versus 2.6 L/h; P = 0.013).
By incorporating CVVH intensity into the CIV dosing nomogram, the majority of patients achieved therapeutic concentrations at 24 h and maintained them within range at 48 and 72 h. Additional studies are required to validate this nomogram before widespread implementation may be considered.
在连续静脉-静脉血液滤过(CVVH)期间达到治疗性万古霉素浓度的最佳方法仍不清楚。研究表明,与间歇性输注相比,连续输注万古霉素(CIV)可更快速且一致地达到目标浓度。已经注意到 CVVH 强度与万古霉素清除率(CLvanc)之间存在正相关。这项研究首次评估了在接受 CVVH 的患者中使用包含基于体重的 CVVH 强度(mL/kg/h)的 CIV 方案的方案。
这是一项前瞻性、观察性研究,研究对象为接受基于方案的 CVVH 和 CIV 的患者。主要结局是在 24 小时时达到治疗性万古霉素浓度(15-25mg/L)。次要结局包括在 48 和 72 小时时达到治疗浓度。
对 52 名危重症成人进行了方案分析。在 24 小时时,43/52 名患者(82.7%)的万古霉素浓度具有治疗作用。在 24 小时时未达到治疗作用的 9 名患者中,有 7 名患者为超治疗浓度,2 名患者为治疗浓度不足。24 小时时的平均(SD)浓度为 20.1(4.2)mg/L,48 小时时为 20.7(3.7)mg/L,72 小时时为 21.9(3.5)mg/L。CVVH 强度>20mL/kg/h 的患者与 CVVH 强度<20mL/kg/h 的患者相比,在 24 小时时的 CLvanc 更高(3.1 与 2.6L/h;P=0.013)。
通过将 CVVH 强度纳入 CIV 给药方案,大多数患者在 24 小时时达到治疗浓度,并在 48 和 72 小时时保持在范围内。在广泛实施之前,需要进行更多的研究来验证该方案。